The Korean Society of Heart Failure guidelines recommend comprehensive management of cardiovascular and non-cardiovascular comorbidities to improve clinical outcomes in patients with heart failure.
This guideline outlines the recommended management strategies for various comorbidities in patients with heart failure to optimize clinical outcomes.
-VASc scores. Valvular heart diseases should be treated medically and/or surgically. In patients with HF and DM, metformin is relatively safer; thiazolidinediones cause fluid retention and should be avoided in patients with HF and dyspnea. In renal insufficiency, both volume status and cardiac performance are important for therapy guidance. In patients with HF and pulmonary disease, beta-blockers are underused, which may be related to increased mortality. In patients with HF and anemia, iron supplementation can help improve symptoms. In obstructive sleep apnea, continuous positive airway pressure therapy helps avoid severe nocturnal hypoxia. Appropriate management of comorbidities is important for improving clinical outcomes in patients with HF.
Park et al. (Sun,) conducted a review in Heart Failure with comorbidities. Guideline-directed management of comorbidities was evaluated. The Korean Society of Heart Failure guidelines recommend comprehensive management of cardiovascular and non-cardiovascular comorbidities to improve clinical outcomes in patients with heart failure.